The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces NK cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients

被引：0
|
作者：
Kellner, C. [1 ]
Zhukovsky, E. A. [2 ,3 ]
Brueggemann, M.
Poetzke, A. [1 ]
Schrauder, A. [4 ]
Kneba, M.
Repp, R. [1 ]
Humpe, A. [1 ]
Gramatzki, M. [1 ]
Peipp, M. [1 ]
机构：
[1] Univ Kiel, Sekt Stammzell & Immuntherapie 2, Med Klin & Poliklin, Kiel, Germany
[2] Xencor Inc, Monrovia, CA USA
[3] Univ Klinikum Schleswig Holstein, Med Klin & Poliklin 2, Kiel, Germany
[4] Univ Klinikum Schleswig Holstein, Klin Allgemeine Padiat, Kiel, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：185 / 185
页数：1
相关论文
共 22 条
  • [1] The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients
    C Kellner
    E A Zhukovsky
    A Pötzke
    M Brüggemann
    A Schrauder
    M Schrappe
    M Kneba
    R Repp
    A Humpe
    M Gramatzki
    M Peipp
    Leukemia, 2013, 27 : 1595 - 1598
  • [2] The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients
    Kellner, C.
    Zhukovsky, E. A.
    Poetzke, A.
    Bruegemann, M.
    Schrauder, A.
    Schrappe, M.
    Kneba, M.
    Repp, R.
    Humpe, A.
    Gramatzki, M.
    Peipp, M.
    LEUKEMIA, 2013, 27 (07) : 1595 - 1598
  • [3] The CD19 Antibody MOR208 Efficiently Triggers Natural Killer Cell-Mediated Cytotoxicity Against Acute Lymphoblastic Leukemia Cells From Pediatric and Adult Patients
    Kellner, Christian
    Zhukovsky, Eugene A.
    Brueggemann, Monika
    Kneba, Michael
    Schrauder, Andre
    Schrappe, Martin
    Repp, Roland
    Humpe, Andreas
    Gramatzki, Martin
    Peipp, Matthias
    BLOOD, 2012, 120 (21)
  • [4] A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL
    Woyach, Jennifer A.
    Awan, Farrukh
    Flinn, Ian W.
    Berdeja, Jesus G.
    Wiley, Elizabeth
    Mansoor, Sharmeen
    Huang, Ying
    Lozanski, Gerard
    Foster, Paul A.
    Byrd, John C.
    BLOOD, 2014, 124 (24) : 3553 - 3560
  • [5] An Fc-engineered CD19 antibody engages NK cells and macrophages and is effective in Xenograft models of acute lymphoblastic leukemia
    Kellner, C.
    Alsadeq, A.
    Cario, G.
    Vieth, S.
    Rosskopf, S.
    Burmeister, Y.
    Klausz, K.
    Valerius, T.
    Schrappe, M.
    Gramatzki, M.
    Peipp, M.
    Schewe, D. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 202 - 202
  • [6] An Fc-Engineered CD19 Antibody Engages Macrophages and Is Effective in Xenograft Models of Pediatric Acute Lymphoblastic Leukemia
    Schewe, Denis M.
    Alsadeq, Ameera
    Cario, Gunnar
    Vieth, Simon
    Valerius, Thomas
    Schrappe, Martin
    Gramatzki, Martin
    Peipp, Matthias
    Kellner, Christian
    BLOOD, 2016, 128 (22)
  • [7] A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL)
    Woyach, Jennifer A.
    Ruppert, Amy S.
    Awan, Farrukh
    Jones, Jeffrey A.
    Waymer, Sharon
    Lozanski, Gerard
    Muthusamy, Natarajan
    Byrd, John C.
    BLOOD, 2015, 126 (23)
  • [8] XmAb5574: In vitro and in vivo efficacy of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia and its effect on B cells in non-human primates
    Zhukovsky, E.
    Horton, H.
    Lawrence, C. E.
    Chu, S.
    Pong, E.
    Richards, J.
    Peipp, M.
    Repp, R.
    Desjarlais, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts
    Schewe, Denis M.
    Alsadeq, Ameera
    Sattler, Cornelia
    Lenk, Lennart
    Vogiatzi, Fotini
    Cario, Gunnar
    Vieth, Simon
    Valerius, Thomas
    Rosskopf, Sophia
    Meyersieck, Fabian
    Alten, Julia
    Schrappe, Martin
    Gramatzki, Martin
    Peipp, Matthias
    Kellner, Christian
    BLOOD, 2017, 130 (13) : 1543 - 1552
  • [10] Final Results of a Phase I Study of the Fc Engineered CD19 Antibody XmAb®5574 (MOR00208) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
    Woyach, Jennifer A.
    Awan, Farrukh
    Flinn, Ian W.
    Enoch, Rolondo
    Foster, Paul A.
    Byrd, John C.
    BLOOD, 2012, 120 (21)
123